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Exercise trainingBackground: Recent evidence suggests that routine exercise-based cardiac rehabilitation (CR) may not lead to a
substantial increase in estimated peak oxygen uptake (V̇O2peak). This could reduce the potential beneﬁts of CR
and explain why CR no longer improves patient survival in recent studies. We aimed to determine whether rou-
tine exercise-based CR increases V̇O2peak using gold-standardmaximal cardiopulmonary exercise testing (CPET),
and to quantify the exercise training stimulus which might be insufﬁcient in patients undertaking CR.
Methods:We studied the effects of a routine, twiceweekly, exercise-based CR programme for eight weeks (inter-
vention group) comparedwith abstention from supervised exercise training (control group) in patientswith cor-
onary heart disease. The primary outcomewas V̇O2peakmeasured using CPET.We alsomeasured changes in body
composition using dual X-ray absorptiometry, carotid intima-media thickness, hs-CRP andN-terminal pro B-type
natriuretic peptide at baseline, 10weeks and 12months.We also calculated the Calibre 5-year all-causemortality
risk score.
Results: Seventy patients (age 63.1 SD10.0 years; BMI 29.2 SD4.0 kg·m−2; 86%male) were recruited (n= 48 in-
tervention; n = 22 controls). The mean aerobic exercise training duration was 23 min per training session, and
themean exercise training intensitywas 45.9% of heart rate reserve. V̇O2peakwas 23·3ml·kg
-1·min−1 at baseline,
and therewere no changes in V̇O2peak between groups at any time point. The intervention had no effect on any of
the secondary endpoints.
Conclusion: Routine CR does not lead to an increase in V̇O2peak and is unlikely to improve long-term physiological
outcomes.
© 2020 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Cardiac rehabilitation (CR) is a suite of medical and lifestyle second-
ary prevention measures for patients with heart disease, including cor-
onary heart disease (CHD). Exercise training is a key part of a CR
programme in the United Kingdom (UK) [1]. Long-term adherence to
exercise-based CR can reduce total cholesterol and LDL-cholesterol,
and increases HDL cholesterol [2]. It can reduce the progression ofaire@hewison.net (C. Taylor),
R. Page),
ion@hull.ac.uk (F. Nation),
.T. Birkett), s.carroll@hull.ac.uk
eliability and freedom from bias
. This is an open access article undercoronary atheroma [3], reduce myocardial remodelling [4], and in-
creases survival [5]. Systematic reviews conducted in 2004 [6] and
2011 [7] reported that compared to standard medical care, exercise-
based CR improved survival and reduced the number of hospital admis-
sions by up to 20% and 31%, respectively, in patients with CHD [6,7].
However, a more recent clinical trial [8] and two recent systematic re-
views [9,10] suggest that exercise-based CR might not improve all-
cause mortality [9], cardiovascular mortality [10], or recurrent cardio-
vascular events [9] in patients with CHD. This may be because modern
revascularisation techniques, such as thrombolysis and percutaneous
coronary intervention, improve both short and long-term patient sur-
vival [11,12]. However, the authors of a recent systematic review [10],
a previous clinical trial [13], and research letters [14,15] have also spec-
ulated that low exercise training doses may also be responsible.
The “dose” of exercise training delivered to patients attending
exercise-based CR is an important consideration because anthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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quate physiological stimulus to invoke positive physiological ad-
aptations. Increasing V ̇O2peak is central to improving patient
survival. In patients with CHD, a 1% improvement in V ̇O2peak is
associated with a 2% reduction in cardiovascular mortality risk
over approximately ﬁve years [16], and a 3.5 ml·kg−1 min−1 in-
crease in V ̇O2peak confers a 25% reduction in all-cause mortality if
improvements are maintained for more than one year [17].
However, it is not clear whether routine CR results in an increase in
V̇O2peak that is sufﬁcient to improve clinical outcomes, including sur-
vival. A UKmulti-centre study including 950 patients reported that esti-
mated V̇O2peak increased by as little as 1.8 ml∙kg∙−1 min−1 (0.52 METs)
following six to eight weeks (6 to 16 sessions) of exercise-based CR
[13]. We have shown that estimated V̇O2peak over-estimates measured
changes in V̇O2peak by 0.7ml∙kg∙−1min−1 (−4·7 to 5·9ml∙kg∙−1min−1)
[18]. Thus, improvements in peak aerobic ﬁtness resulting from routine
exercise-based CR in the UKmay beminimal.We therefore aimed to as-
sess the short (10 weeks) and longer-term (12 months) effect of stan-
dard exercise-based CR on directly measured V ̇O2peak using gold-
standardmaximal cardiopulmonary exercise testing.We alsomeasured
markers of cardiovascular/metabolic health including, dual X-ray ab-
sorptiometry (DXA)-derived measurements of body composition, ca-
rotid intima-media thickness (C-IMT), high sensitivity C-reactive
protein (hs-CRP) and N-terminal pro B-type natriuretic peptide (NT-
proBP) and blood lipid/glucose proﬁles.We hypothesised that a routine,
8 week, 16 session, exercise-based CR programme would lead to an in-
crease in V̇O2peak, and that the V̇O2peak of control patients who declined
to participate in exercise-based CR would not change.
2. Methods
Reporting of ﬁndings adhere to STROBE guidelines (supplementary
ﬁle). Baseline patient data [19,20] andmethods [21] have been reported
elsewhere. Clinically stable patients with a recent diagnosis of angina,
myocardial infarction (MI), coronary artery bypass graft (CABG) surgery
or elective percutaneous coronary intervention (PCI) were recruited be-
tween 12th March 2014 and 5th December 2016. All patients were re-
cruited following their referral to a local Phase III CR programme.
Patients were free to participate in a routine exercise-based CR pro-
gramme(intervention group), or to abstain freely from supervised exer-
cise (control group). Patients in the intervention group underwent an
initial assessment approximately one week before commencing their
CR programme and were followed up approximately one week after
completing their CR programme. Patients in the control group were
assessed approximately twoweeks after they declined their CR pro-
gramme and were reassessed approximately 10 weeks after their initial
assessment. All patients receiveda follow-upassessment after12months.
Patients were asked to attend the research laboratory having not partic-
ipated in strenuous exercise within the previous 24 h.
Ethical approval was obtained from the Humber Bridge NHS Re-
search Ethics Committee – Yorkshire and the Humber (13/YH/0278).
Study procedures conform to the 1975 Declaration of Helsinki. Written
informed consent was obtained prior to conducting any investigations.
2.1. Anthropometric measurements
Height (cm)wasmeasured using a Leicester Height Measure (SECA,
Birmingham, UK).Waist circumferencemeasurementswere taken from
1 cm above the iliac crest, and hip measurements were taken from the
widest aspect of the buttocks.
2.2. Resting measurements
Resting heart rate was recorded using a 12‑lead ECG (GE Healthcare,
Buckinghamshire, UK) and resting blood pressure was measured using
an automated blood pressure cuff (Tango, SunTech Medical, Eynsham,UK). Pulse wave velocity was then measured using Vascular Explorer
(Enverdis GmbH, Düsseldorf, Germany). Measurements were taken be-
tween the brachium and ankle by placing a blood pressure cuff above
the left cubital fossa (brachial artery) and above the medial malleolus.
Photoplethysmographic sensors were placed on the patients left index
ﬁnger and left hallux. Echocardiography (Vivid 9, GE, USA) was used
to measure left ventricular ejection fraction (LVEF) using Simpson's
method following the guidelines of Lang and colleagues [22]. Left-
ventricular systolic dysfunction was deﬁned as LVEF ≤45%.2.3. Blood samples
Haematocrit and haemoglobin concentrations, neutrophil and lym-
phocyte count andNT-proBNPweremeasured in an accredited National
Health Service laboratory on the day that blood samples were collected.
Non-fasting plasma glucose and serum hs-CRP were analysed in dupli-
cate using the ABX Pentra 400 biochemistry auto analyser (Horiba,
Montpellier, France) using frozen plasma and serum samples. Calibra-
tion and quality controls were conducted in accordance with manufac-
turers' guidelines.2.4. Dual X-ray absorptiometry
Body composition was determined using DXA (Lunar iDXA, 255 GE
Healthcare) as previously described [20,21]. Total body mass (kg),
lean body mass (kg) and total fat mass (%) were determined using the
Lunar iDXA's integrated software. Appendicular lean mass (ALM; total
lean mass in both arms and legs) was calculated (kg) and standardised
to their height squared; (skeletal muscle index; SMI kg·m−2). ALMwas
also reported as a percentage of total body mass (appendicular skeletal
mass; ASM%). Low skeletal muscle mass was deﬁned as an SMI of
b7.0 kg·m−2 for men, and b6.0 kg·m2 for women [23].2.5. Carotid intima-media thickness measurements
Carotid intima-media thickness measurements were made with the
Panasonic CardioHealth Station (Panasonic Biomedical Sales Europe BV,
Leicestershire, UK), as previously described [21,24].2.6. Maximal cardiopulmonary exercise testing
The modiﬁed Bruce treadmill protocol was used for maximal CPET
[25] and our testing practices adhered to established guidelines
[26–28]. Heart rate (12‑lead ECG) and blood pressure (ECG-gated cuff)
were recorded at the second minute of each three minute test stage.
Rating of perceived exertion (RPE) scores (6–20) were recorded at
peak exercise (Borg, 1982). Breath-by-breath metabolic gas exchange
data were collected using an Oxycon Pro metabolic cart (Jaeger,
Hoechburg, Germany). Metabolic gas exchange data were exported for
ofﬂine analysis using Microsoft Excel (Washington, USA). Peak oxygen
uptake was deﬁned as the mean V ̇O2 (ml) over the last 30 s of the
CPET, and was adjusted for body mass (ml·kg−1·min−1). The ventila-
tory anaerobic threshold (VAT)wasdetermined by two independent in-
vestigators (SN & FN) using the V-slope method [29]. The VAT was
analysed using data from the middle ﬁve of seven consecutive breaths.
The VATwas reported in ml and standardised to bodymass (ml·kg−1·-
min−1). Oxygen pulse (V̇O2/HR), V̇E/V̇CO2 slope and oxygen uptake ef-
ﬁciency slope (OUES) were calculated as previously described [28].
Directly determined metabolic equivalents were calculated by dividing
each patient's V̇O2peak (ml.kg-1.min-1) by 3.5 [30]. Estimatedmetabolic
equivalents were calculated according to the American College of Sport
Medicine (ACSM) metabolic equation for walking [31].
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Five-year mortality risk was estimated for each patient using the on-
line (https://www.caliberresearch.org/model) Calibre 5-year risk calcula-
tor [32], and reported as a percentage. Themodel has good calibration and
discrimination in internal and external validation (C-Index 0.811) for all-
cause mortality. Variables included in the model are shown in Appendix
1. Themodel does not include anyﬁtnessmeasurements in its calculation.
2.8. Exercise training programme
Patients in the intervention group participated in a physiotherapist-
led, eightweek, 16 session (twiceweekly) personalised exercise training
programme, which was prescribed according to UK CR guidelines [33].
Patientswere also instructed to participate in additional home-based ex-
ercise training sessions at the discretion of the physiotherapist. Each ex-
ercise training session incorporated nine exercises which initially
alternated between cardiovascular (CV) exercise training and active re-
covery (AR) stations. Examples of the exercises provided included cy-
cling, treadmill walking, rowing, knee raises, stepping, marching on
the spot, arm curls and sit-to-stands. During the course of the eight
week CR programme, AR stations were replaced with CV stations to in-
crease difﬁculty and to increase the total duration of CV exercise train-
ing. The aim was for patients to be able to complete a minimum of
20 min of CV exercise training at each exercise session, by the end of
the eight week CR programme [33]. Aerobic exercise intensity was pre-
scribed at 40–70% of a patient's heart rate reserve (HRR), which was es-
timated using the following formula [34]:
((206–0.7 × age) - resting heart rate)
A further 30 beats per minute was deducted from estimatedmaximal
heart for patients who were taking beta-blockers [33]. Patients were
asked to record their peak heart rate after each exercise station. The
Borg rating of perceived exertion (RPE; 6–20 scale) was used to help pa-
tients regulate their exercise intensity [35]. Patients were asked to exer-
cise at an intensity corresponding to an RPE of 11 to 14 [33]. Exercise
intensity was up-titrated by increasing cadence or resistance of exercise
based on preference and/or the ability of the patient. The total duration
of CV training was calculated for each of the 16 exercise sessions. The in-
tensity of aerobic exercise training was characterised by reporting the
median peak heart rate from each CV exercise station and was expressed
relative to HRR, and HR at VAT (determined during CPET).
2.9. Study protocol and statistical analysis
As previously reported [21], an initial calculation assuming 90%
power to detect a 2 ml∙kg−1 min−1 (SD 4 ml∙kg−1 min−1) difference
in V̇O2peak between the two groups after the intervention lead to a target
sample size of 203 (assuming 15% attrition). As planned [21], the sample
size calculation, based on the differences in V̇O2peak (ml∙kg∙−1 min−1) at
the 10-week assessment, was repeated after the ﬁrst 70 patients had
completed the study. The mean V ̇O2peak in the exercise intervention
and control group was 24.1 SD 5.0 ml∙kg∙−1 min−1, and 22.9 SD
5.4 ml∙kg∙−1 min−1, respectively. The allocation ratio was 2/1 in favour
of the intervention group. A total sample size of n = 864 patients was
required to achieve a statistical power of 90% (n= 288 in the interven-
tion group and n = 576 in the control group). As only 30 patients were
being recruited per year, the study was suspended at 70 patients given
the unattainable target required.
Statistical analysis was conducted using SPSS version 24 (IBM, New
York, NY, USA). Data were visually assessed for normality, and by
using the Shapiro-Wilk test. Categorical data are presented as frequency
and percentages. Continuous normally distributed data are presented as
mean with standard deviation (SD) or 95% conﬁdence intervals (CI), as
speciﬁed. Where data was missing or participants were lost to follow-
up, the last known data point was carried forward. A per-protocol anal-
ysis was also conducted on the primary outcome measure (V̇O2peak).Statistically signiﬁcant differences (P b 0.05) were assessed using a
one-way analysis of variance (ANOVA) or a repeated measure ANOVA
with between group interactions, as appropriate. Corresponding partial
eta (ηp2) effect sizeswere used to report themagnitude of group differ-
ences. Effect sizes of 0.01, 0.06, and 0.140 denoted small, moderate, and
large effect sizes, respectively [36], Friedman and Mann-Whitney U
analyses were used to detect signiﬁcant differences between non-
parametric variables. Chi squared analysis was used to detect signiﬁcant
differences between categorical variables.
3. Results
3.1. Patient characteristics
Onehundred and forty-nine (n=149)patientswhomet the study in-
clusion criteria were invited to participate in the study. Seventy-nine
(n=79) patients declined to participate in the study due to lack of inter-
est or time. Seventy patients were recruited (age 63.1 SD10.0 years; BMI
29.2 SD4.0 kg·m−2; 86%male). Forty-eight patientswere recruited to the
intervention group, and 22 patients opted to participate in the control
group. Five patients from the intervention group and one from the control
group were lost to follow-up at 10 weeks (10 week sample n= 64). One
patient in the intervention group died from a spontaneous intracranial
haemorrhage between 10 weeks and 12 months. One patient in the con-
trol groupdied frompneumonia between10weeks and12months. A fur-
ther four patients from the intervention group and ﬁve controls were lost
to follow-up at 12 months (12 month sample n = 53).
Missing data are summarised in Appendix 2. The baseline clinical
characteristics of the patients in each group were similar (Table 1),
but more control patients had diabetes (36% v 13%; P = 0.020), and
more control patients were smokers (18% v 0%; p = 0.023). There
were no differences in prescribed secondary prevention medications
between the two groups (Appendix 3). Approximately half the patients
(54%) were referred to CR following a MI. The median time between
hospital discharge and study consent was 54 days (range 22 to 220).
3.2. Exercise training dose
Patients in the intervention group attended a median of 16 super-
vised exercise sessions (range: 6 to 16). Thirty-six (75%) patients
attended all 16 sessions, and four (8%) attended b14 sessions. Patients
in the intervention group took part in amedian of one (range: 0 to 8) ad-
ditional self-directed home-based exercise session per week. However,
the cumulative number of weekly supervised and home-based exercise
sessions undertaken by patients in the intervention group was still two
(range 2 to 10 sessions). In the controls, the total number of reported
weekly self-directed home-based exercise sessions was zero (range: 0
to 7; P = 0.003). The duration and intensity of self-directed exercise
training conducted by control patients was not recorded.
The median CV training duration at the ﬁrst supervised CR exercise
session was 12 min (range: 4 to 28 min), which increased to 23 min at
theﬁnal exercise session (range: 11 to 50min; P b 0.001). The exercise in-
tensity during CV training increased over the course of the intervention.
The mean peak heart rate was 93 bpm (95% CI: 88–98 bpm) during the
ﬁrst session, corresponding to 46% (95% CI: 40–52%) of directly deter-
mined HRR, or 97% of mean heart rate at VAT (95% CI: 92–101%). By the
end of the 8 week programme, the mean peak heart rate had increased
to 97 bpm (95% CI: 92–101 bpm; P = 0.015), or 54% of HRR (95% CI:
47–61%; P = 0.011), but the mean peak HR as a %HR at the VAT (at
10 weeks), did not increase (102%; 95% CI 97–106%; P= 0.076).
3.3. Maximal cardiopulmonary exercise testing
The mean V̇O2peak of patients and controls was similar at baseline
(Table 2). There was no change in V ̇O2peak in either group after
10 weeks (main effect P = 0.637 ηp2 = 0.004; interaction effect P =
Table 1
Patient characteristics (mean SD standard deviation).
Patient characteristics All (n = 70) Control group (n = 22) Exercise group (n = 48) P-value
Males (%) 60 (86) 20 (90.9) 40 (83.3) 0.400
Age (years) 63.1 SD 10.1 62.0 SD 10.1 63.7 SD 7.0 0.509
BMI (kg·m−2) 29.2 SD 4.0 29.4 SD 4.9 28.9 SD 3.5 0.633
Waist to hip ratio 0.97 SD 0.07 0.98 SD 0.06 0.96 SD 0.07 0.125
Appendicular lean mass (kg) 23.8 SD 4.7 24.3 SD 4.3 23.5 SD 4.9 0.492
SMI (kg·m−2) 8.7 SD 1.7 8.9 SD 1.6 8.6 SD 1.8 0.492
ASM (%) 28.1 SD 3.6 28.7 SD 3.5 27.8 SD 3.6 0.290
Haemodynamic measurements
Resting HR (bpm) 59 SD 11 59 SD 12 59 SD 12 0.919
Resting systolic BP (mmHg) 128 SD 20 129 SD 24 128 SD 18 0.860
Resting diastolic BP (mmHg) 81 SD 13 84 SD 17 80 SD 11 0.227
LV ejection fraction (%) 55.0 SD 6.9 54.4 SD 8.2 55.3 SD 6.2 0.637
LV end systolic volume (ml) 54.3 SD 17.0 51.8 SD 17.0 55.4 SD 17.1 0.418
LV end diastolic volume (ml) 116.0 SD 28.0 112.4 SD 14.4 117.7 SD 29.7 0.471
LV end systolic diameter (cm) 36.0 SD 5.9 36.4 SD 5.5 35.8 SD 6.2 0.679
LV end diastolic diameter (cm) 50.5 SD 5.6 50.3 SD 4.8 50.6 SD 6.0 0.822
Intraventricular septal thickness (cm) 9.7 SD 1.6 9.9 SD 1.9 9.6 SD 1.6 0.513
Blood biomarker measurements
Total cholesterol (mmol/L)‡ 3.6 (2.1 to 6.14) 3.5 (2.2 to 5.9) 3.6 (2.1 to 6.1) 0.786
LDL-cholesterol (mmol/L)‡ 1.6 (0.8 to 4.0) 1.6 (0.9 to 3.5) 1.6 (0.8 to 4.0) 0.885
HDL-cholesterol (mmol/L)‡ 1.1 (0.6 to 2.1) 1.1 (0.8 to 1.8) 1.1 (0.6 to 2.1) 0.815
Triglycerides (mmol/L)‡ 1.3 0.5 to 4.6) 1.3 (0.5 to 4.4) 1.4 (0.5 to 4.6) 0.923
High Sensitivity-CRP (mg/L)‡ 1.3 (0.1 to 16.6) 1.5 (0.2 to 16.6) 1.3 (0.1 to 9.7) 0.374
Blood Glucose (mmol/L)‡‡ 5.6 (3.3 to 22.2) 5.6 (3.3 to 13.8) 5.5 (4.5 to 22.2) 0.775
NT-proBNP (ng/L)‡ 187.0 (11.4 to 2735.0) 195.5 (20.3 to 2735.0) 187.0 (11.4 to 1916.0) 0.854
eGFR (mL/min/1.73m2)‡ 82.0 (38.0 to 90.0) 83.5 (53.0 to 90.0) 81.5 (38.0 to 90.) 0.144
Haemoglobin (g/L)‡ 140.0 (83.0 to 165.0) 140.5 (122.0 to 165.0) 139.5 (83.0 to 165.0) 0.471
Haematocrit (%)‡ 41.4 (23.7 to 47.1) 41.1 (36.1 to 45.3) 41.5 (23.7 to 47.1) 0.603
Spirometry measurements
Peak expiratory ﬂow (L/s) 7.9 SD 2.1 7.4 SD 2.0 8.1 SD 2.1 0.244
FEV1 (L) 2.9 SD 0.7 2.9 SD 0.7 2.9 SD 0.7 0.897
FVC (L) 3.8 SD 0.8 3.9 SD 0.9 3.8 SD 0.8 0.736
FEV1/FVC ratio 0.76 SD 0.08 0.75 SD 0.08 0.77 SD 0.08 0.327
Presenting diagnosis
Myocardial infarction (%) 38 (54) 14 (64) 24 (50) 0.710
Percutaneous coronary intervention (%) 19(27) 5 (23) 14 (29)
Angina (%) 7 (10) 2 (9) 5 (10)
Coronary artery bypass graft (%) 6 (9) 1 (5) 5 (10)
Past medical history
Myocardial infarction (%) 15 (21) 5 (23) 10 (21) 0.747
Percutaneous coronary intervention (%) 16 (23) 6 (23) 11 (23) 0.793
Coronary artery bypass graft (% 5 (7) 2 (9) 3 (6) 0.668
Cardiac valve surgery (%) 1 (1) 1 (5) 0 (0) 0.137
Cerebrovascular accident (%) 6 (9) 1 (5) 5 (10) 0.415
Atrial ﬁbrillation (%) 5 (7) 1 (5) 4 (8) 0.445
Asthma (%) 8 (11) 1 (5) 7 (15) 0.220
Chronic obstructive pulmonary disease (%) 4 (6) 2 (9) 2 (4) 0.410
Hypertension (%) 33 (47) 13 (59) 20 (42) 0.175
Hyperlipidaemia (%) 47 (67) 14 (64) 33 (69) 0.672
Type II diabetes (%) 14 (20) 8 (36) 6 (13) 0.020⁎
Cancer (%) 10 14) 4 (18) 6 (13) 0.528
Behavioural risk factors
Number of patients achieving 150 min of moderate physical activity per week (%) 32 (46) 8 (36) 24 (50) 0.322
Number of patients achieving 75 min of vigorous physical activity per week (%) 8 (11) 3 (14) 5 (10) 0.660
Weekly alcohol units consumed‡ 4 (0 to 70) 4 (0 to 46) 4 (0 to 70) 0.622
Smoker (%) 4 (6) 4 (18) 0 (0) 0.023⁎
Ex-smoker (%) 43 (61) 13 (59) 30 (63)
Hospital anxiety and depression score (anxiety)‡ 4 (0 to 15) 4 (0 to 11) 4 (0 to 15) 0.670
Hospital anxiety and depression score (depression)‡ 2 (0 to 13) 1 (0 to 9) 3 (0 to 13) 0.157
BMI=bodymass index; SMI= skeletalmuscle index; ASM=appendicular skeletal mass; HR=Heart Rate; bpm=beats perminute; BP=blood pressure; LV= left ventricle; CRP=C-
reactive protein; NT-proBNP=N-terminal brain-type natriuretic peptide; eGFR= estimated glomerular ﬁltration rate; FEV1= forced expired volume in 1 s; FVC= forced vital capacity.
⁎ Signiﬁcant difference.
‡ non-parametric data.
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interaction effect P = 0.733; ηp2 = 0.006). Fig. 1 shows the individual
changes in V̇O2peak and VAT at 10 weeks. Approximately 57% (n = 24)
of intervention patients and 43% (n = 9) of controls had a higher
V̇O2peak after 10weeks. A greater proportion of patients in the interven-
tion (68%; n= 23) and control groups (60%;n= 9) had a higher V̇O2peak
at 12 months compared with baseline measurements, however the
number of patients with a higher V ̇O2peak remained similar (Fig. 1).
There were no changes in the VAT at any time point.
There were no differences between groups for other CPET-derived
variables. The VE/VCO2 slope decreased between baseline and week
10 (main effect: -1.1; 95% CI -1.9 to 0.4; P = 0.003), and between
week 10 and 12 months in both groups (main effect: -0.6; 95% CI -1.2
to −0.1; P = 0.024). Peak RER was higher than baseline values at
week 10, and 12 months in both groups (P= 0.001).
3.4. Cardiovascular/metabolic risk proﬁle
There were no changes in right- (P= 0.236), or left-sided, mean C-
IMT measurements in either group (P= 0.401) at any time point. Body
mass index increased in both groups between baseline and 12 months
(main effect: 0.4 kg∙m−2; 95% CI 0.1–0.7 kg∙m−2; P = 0.011), and be-
tween 10 weeks and 12 months (main effect: 0.3 kg∙m−2; 95% CI
0.1–0.5 kg∙m−2; P = 0.016; Table 3). Appendicular skeletal mass
was lower in both groups after 10 weeks compared to baseline (main ef-
fect: −0.3%; 95% CI -0.1 to −0.5%; P = 0.007). There was a further
reduction at 12 months compared to week 10 (main effect:−0.8%; 95%
CI -0.1- to −1.5%; P = 0.018). Compared to baseline values (187;
11–2735 mg∙dl−1), NT-proBNP was signiﬁcantly lower in both groups
after 10 weeks (main effect: 156; 13–1695 mg∙dl−1; P=0.003), and de-
creased further at 12 months (main effect: 137; 9–1695 mg∙dl−1; P =
0.003). NT-proBNP was also signiﬁcantly lower after 12 months com-
pared to 10weeks (P=0.011). Pulse wave velocity, lipids, blood glucose,
and NT-proBNP did not differ by group (all P N 0.050). There were no dif-
ferences between the two groups in any of the variables measured.
3.5. Calibre 5-year all-cause mortality risk
The median calculated mortality risk at baseline, 10 weeks, and
12 months is shown in Appendix 4. It was the same in each group at
each time point.
4. Discussion
The primary aim of this controlled study was to determine whether
a routine 8week, 16 session, exercise-based CR programme led to an in-
crease in V̇O2peak. Peak oxygen uptake did not change in our interven-
tion or control group after 10 weeks or 12 months. However, our
study did not recruit as many patients as planned [21] and may there-
fore lack sufﬁcient statistical power to detect a signiﬁcant difference in
our primary outcome measure. It is important to note, however, that
the effect sizes for the mean differences between the intervention and
control group were small. Furthermore, our planned interim sample
size calculation [21] indicated that an additional 794 patients would
be required to achieve sufﬁcient statistical power. We estimated that
it would take our single centre study another 30 years to recruit this
many patients, and we therefore suspended recruitment. The number
of patients needed to detect a signiﬁcant difference between the inter-
vention and control groups is higher than those reported by previous
studies [3,37]. Our study therefore provides further evidence [13,18]
that the dose of exercise prescribed to patients attending routine CR in
the UK may not be high enough to improve V̇O2peak.
Our data, obtained using gold-standard maximal CPET, agree with
previous data showing that exercise-based CR in the UK leads to a
small improvement in estimated V̇O2peak [13] when compared to inter-
national programmes [38]. However, it is important to consider the
Fig. 1. Individual changes in V̇O2peak and the VAT after 10 weeks. Black lines indicate exercise training responses for patients undertaking the intervention, and grey lines indicate exercise
training responses for controls.
30 S. Nichols et al. / International Journal of Cardiology 305 (2020) 25–34measurement error incurred from estimating changes in V̇O2peak. Data
obtained fromwalking-based exercise test protocols conductedwithout
metabolic gas exchange shows that UKCR leads to an estimatedMET in-
crease of up to 0.76METs (0.40 to 1.12 METs) [13]. Data from our study
suggests that estimated changes in peak aerobic ﬁtness [31]may lead to
a 0.7 MET increase without concurrent changes in V ̇O2peak (Table 2).
This suggests that the changes in V̇O2peak reported in previous studies
[13] could be smaller than previously thought. This is important because
increasing a patient's V ̇O2peak is a key mechanism by which CR was
thought to improve patient survival [16,17]. Smaller than expected im-
provements in V̇O2peakwithinUKCRprogrammes [13,18]may therefore
partly explain why CR no longer appears to improve patient survival or
hospital admissions [9,10].
Recent evidence from the UK showed that patients attending 332 CR
exercise training sessions similar to those used in our study, exercised at
37.1% of their HRR [39]. Data from our study shows that the intensity ofaerobic exercise training conducted by our patients was slightly higher
than this (46–54% HRR), but remained conservatively within UK na-
tional guidelines (40–70% HRR) [33]. However, our data were derived
from peak exercise training heart rate values and is therefore likely to
overestimate the average exercise intensity. Furthermore, patients
were only exercising for 23 min by the end of the eight week CR pro-
gramme,which onlymarginally exceeds theUK'sminimum recommen-
dations of 20 min [33]. The low dose of exercise may explain why
V̇O2peak, markers of cardiometabolic health, C-IMT, and Calibre 5-year
all-causemortality risk did not change following exercise-based CR. Ex-
ercise training conducted over 6 [40] to 12 months [3] has been shown
to attenuate the progression of atherosclerosis in patients with CHD.
Supporting patients to undertake higher doses of exercise training
within a structured exercise training programme or as part of a home-
based prescription may help to improve these important clinical
outcomes.
Table 3
Cardiometabolic risk factors (mean and 95% conﬁdence intervals).
Risk factor Control group Intervention group P-value Partial eta squared
Baseline Week 10 Month 12 Baseline Week 10 Month 12 Main
effect
Interaction
effect
Main
effect
Interaction
effect
BMI (kg·m−2) 29.4 (27.7 to 31.1)b 29.6 (27.9 to 31.4)c 30.0 (28.1 to 31.9)b,c 28.9 (27.8 to 30.1)b 28.9 (27.7 to 30.1)c 29.1 (27.8 to 30.4)b,c 0.010⁎ 0.230 0.077 0.022
Waist to hip ratio 0.98 (0.96 to 1.01) 0.98 (0.96 to 1.01) 0.99 (0.96 to 1.01) 0.96 (0.94 to 0.97) 0.95 (0.93 to 0.97) 0.95 (0.93 to 0.97) 0.631 0.802 0.007 0.003
Fat mass (kg) 29.4 (25.8 to 33.1) 29.3 (25.5 to 33.1) 29.0 (24.4 to 33.6) 30.3 (27.9 to 32.8) 29.9 (27.3 to 32.5) 29.6 (26.5 to 32.7) 0.454 0.926 0.012 0.001
Android fat (%) 46.1 (42.7 to 49.4) 45.6 (41.9 to 49.2) 46.0 (42.2 to 49.7) 47.1 (44.8 to 49.4) 46.3 (43.8 to 48.8) 46.4 (43.8 to 48.9) 0.206 0.647 0.023 0.050
Android/gynoid ratio 1.31 (1.22 to 1.39) 1.30 (1.22 to 1.38) 1.31 (1.23 to 1.39) 1.23 (1.17 to 1.28) 1.24 (1.18 to 1.29) 1.23 (1.17 to 1.28) 0.876 0.343 0.002 0.015
Lean body mass (kg) 35.9 (33.0 to 38.7) 36.2 (33.4 to 38.9) 36.2 (33.5 to 38.8) 34.9 (32.9 to 36.8) 34.7 (32.9 to 36.6) 34.6 (32.8 to 36.4) 0.918 0.331 0.001 0.016
Appendicular lean mass (kg) 24.3 (22.3 to 26.3) 24.5 (22.5 to 26.5) 23.9 (21.8 to 26.1) 23.5 (22.1 to 24.9) 23.7 (22.3 to 25.1) 23.2 (21.7 to 24.6) 0.088 0.934 0.041 b0.001
Skeletal muscle index (kg/m2) 8.9 (8.2 to 9.6) 8.9 (8.2 to 9.7) 8.8 (8.0 to 9.5) 8.6 (8.1 to 9.1) 8.7 (8.2 to 9.2) 8.5 (8.2 to 9.2) 0.088 0.934 0.041 b0.002
Appendicular skeletal mass (%) 28.7 (27.2 to 30.3)a 28.9 (27.3 to 30.5)a,c 28.0 (26.2 to 29.8)c 27.8 (26.7 to 28.8)a 28.1 (27.0 to 29.2)a,c 27.4 (26.1 to 28.6)c 0.035⁎ 0.727 0.060 0.002
Resting HR (bpm) 59 (55 to 64) 60 (56 to 64) 60 (56 to 64) 59 (56 to 62) 58 (55 to 60) 58 (55 to 60) 0.940 0.223 0.001 0.022
Resting systolic BP (mmHg) 129 (120 to 137) 126 (117 to 135) 129 (120 to 138) 128 (122 to 134) 121 (115 to 127) 123 (117 to 129 0.060 0.518 0.041 0.010
Resting diastolic BP (mmHg) 84 (79 to 90)a,b 77 (72 to 82)a 78 (73 to 82)b 80 (76 to 84)a,b 76 (72 to 79)a 79 (76 to 82)b b0.001⁎ 0.249 0.109 0.020
LV ejection fraction (%) 54.4 (51.5 to 57.3) 53.4 (50.7 to 56.0) 54.5 (51.9 to 57.2) 55.3 (53.3 to 57.2) 55.6 (53.8 to 57.4) 54.8 (53.0 to 56.6) 0.826 0.224 0.003 0.022
LV end systolic diameter (mm) 36.4 (33.9 to 38.9) 36.0 (33.7 38.3) 35.5 (33.4 to 37.6) 35.8 (34.1 to 37.5) 35.8 (34.2 to 37.3) 37.3 (35.9 to 38.7) 0.695 0.095 0.005 0.034
LV end diastolic diameter (mm) 50.3 (47.9 to 52.7) 50.0 (47.9 to 52.2) 50.2 (48.1 to 52.3) 50.6 (47.0 to 52.2) 50.2 (48.7 to 51.6) 50.5 (49.1 to 51.9) 0.802 0.971 0.003 b0.001
LV end systolic volume (ml) 51.8 (44.6 to 59.1) 55.6 (49.0 to 62.2) 54.4 (47.3 to 61.4) 54.4 (47.3 to 61.4) 55.4 (50.5 to 60.3) 54.1 (49.7 to 58.6) 0.571 0.317 0.008 0.017
LV end diastolic volume (ml) 112.4 (100.4 to 124.4) 118.5 (107.5 to 129.5) 117.5 (106.2 to 128.8) 117.7 (109.6 to 125.8) 120.4 (112.9 to 127.8) 120.3 (112.7 to 128.0) 0.179 0.800 0.025 0.003
Carotid-femoral PWV (m/s) 6.8 (5.9 to 7.7) 6.7 (6.1 to 7.4) 6.9 (6.1 to 7.7) 6.7 (6.1 to 7.3) 6.6 (6.2 to 7.1) 6.7 (6.1 to 7.2) 0.900 0.934 0.002 0.001
Brachium-ankle PWV (m/s)‡ 14.9 (10.4 to 53.7) 14.6 (10.4 to 29.6) 14.8 (10.4 to 29.6) 14.8 (10.4 to 28.2) 13.9 (10.4 to 21.10) 14.6 (10.4 to 26.5) 0.096 – – –
Total cholesterol (mmol/L)‡ 3.5 (2.2 to 5.9) 3.6 (2.3 to 5.2) 3.6 (2.1 to 5.2) 3.6 (2.1 to 6.1) 3.6 (2.0 to 6.6) 3.6 (2.1 to 7.8) 0.387 – – –
LDL-cholesterol (mmol/L)‡ 1.6 (0.9 to 3.5) 1.7 (0.9 to 3.3) 1.7 (0.8 to 3.3) 1.6 (0.8 to 4.0) 1.5 (0.6 to 4.0) 1.6 (0.9 to 4.0) 0.681 – – –
HDL-cholesterol (mmol/L)‡ 1.1 (0.8 to 1.8) 1.1 (0.7 to 2.1) 1.1 (0.7 to 2.0) 1.1 (0.6 to 2.1) 1.1 (0.6 to 2.0) 1.2 (0.7 to 2.0) 0.534 – – –
Triglycerides (mmol/L)‡ 1.3 (0.5 to 4.4) 1.3 (0.6 to 4.0) 1.3 (0.6 to 4.1) 1.4 (0.5 to 4.6) 1.3 (0.6 to 4.0) 1.2 (0.6 to 5.2) 0.683 – – –
High sensitivity-CRP (mg/L)‡ 1.5 (0.2 to 16.6) 1.4 (0.2 to 18.5) 0.9 (0.2 to 18.5) 1.3 (0.1 to 9.7) 1.2 (0.1 to 19.1) 1.0 (0.1 to 6.0) 0.412 – – –
Blood glucose (mmol/L)‡ 5.6 (3.3 to 13.8) 6.3 to 4.7 to 16.6) 5.9 (4.3 to 19.9) 5.5 (4.5 to 22.2) 5.5 (4.2 to 22.2) 5.7 (4.5 to 22.2) 0.734 – – –
NT-proBNP (ng/L)‡ 195.5 (20.3 to 2735.0)a,b 145.5 (20.3 to 1331.0)a,c 156.6 (9.1 to 796.0)b,c 187.0 (11.4 to 1916.0)a,b 155.5 (12.6 to 1695.0)a,c 136.0 (19.0 to 1695.0)a,c b0.001⁎ – – –
BMI = body mass index; HR = heart rate; bpm= beats per minute; BP = blood pressure; LV = left ventricle; PWV= pulse wave velocity CRP = C-reactive protein; NT-proBNP = N-terminal brain-type natriuretic peptide.
‡ Non-parametric data.
⁎ Signiﬁcant difference.
a Signiﬁcant difference between baseline and 10 weeks.
b Signiﬁcant difference between baseline and 12 months.
c Signiﬁcant difference between 10 weeks and 12 months.
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Our study was only conducted at one site which may limit the
generalisability of our ﬁndings. Our study sample size was also small,
which also limits the conclusions of our ﬁndings. However, interim
power analysis indicate that we would need to test 864 patients to ﬁnd
a statistically signiﬁcant improvement in V̇O2peak, suggesting that the ob-
served effect signal was small. Furthermore, previous cohort studies
which estimated changes in aerobic ﬁtness following routine exercise-
based CR and have reported similar ﬁndings from CR programmes con-
ducted in other regions of the UK [13]. Finally, we attempted to quantify
the dose of exercise prescribed to patients in the routine exercise-based
CR programme. However, we did not use ‘reference standard’ physical
activity tracking devices such as accelerometers. Thus, we did not accu-
rately determine the dose of exercise prescribed to our patients. We
were therefore unable to determine what dose of exercise was likely to
increase V̇O2peak in patients attending routine exercise-based CR.
5. Conclusion
Whilst our study was underpowered, our data indicates that the
dose of exercise prescribed to patients attending a routine exercise-
based CR programme in the UK may be too low to improve V̇O2peak or
other markers of cardiovascular health. Our ﬁndings should be
interpreted with caution, but may partly explain why CR no-longer ap-
pears to improve clinical outcomes.
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provided during data collection.Appendix 1. Variables included in the CALIBER 5-year risk scoreCategorical variables Continuous variablesex Age (years)
elongs to most deprived quintile Total cholesterol (mmol/L)
AD diagnosis and severity HDL (mmol/L)
terventions (last 6 months) Heart rate (beats per minute)
moking status Creatinine (micromol/L)
ypertension/BP lowering medication White cell count (10^9/L)
iabetes Haemoglobin (g/dl)
eart failure
eripheral arterial disease
trial ﬁbrillation
troke
hronic renal disease
OPD
ancer
hronic liver disease
epression
nxietyACAD = coronary artery disease; HDL high = density lipoprotein; BP = blood pressure; COPD= chronic obstructive pulmonary disease.
Appendix 2. Missing dataInvestigation Number (%) of missing investigations
at baseline (total n = 70)Number (%) of missing investigations
at 10 weeks (total n = 64)Number (%) of missing investigations
at 12 months (total n = 53)PET 0 (0) 1 (2) 4 (8)
XA 0 (0) 1 (2) 1 (2)
chocardiogram 0 (0) 1 (2) 0 (0)
CG 0 (0) 0 (0) 0 (0)
irometry 0 (0) 0 (0) 0 (0)
holesterol Measurements 2 (3) 1 (2) 2 (4)
riglycerides 2 (3) 1 (2) 2 (4)
s-CRP 2 (3) 1 (2) 2 (4)
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C
A
C
Ti
A
B
A
A
St
D
CNumber (%) of missing investigations
at baseline (total n = 70)Number (%) of missing investigations
at 10 weeks (total n = 64)Number (%) of missing investigations
at 12 months (total n = 53)T-proBNP 2 (3) 3 (5) 2 (4)
alibre Risk Score 2 (3) 3 (5) 2 (4)
-IMT 0 (0) 0 (0) 0 (0)CCPET= cardiopulmonary exercise test; DXA= dual X-ray absorptiometry; ECG= electrocardiogram; hs-CRP= high sensitivity C-reactive protein; NT-proBNP=N-terminal brain-type
natriuretic peptide; C-IMT = carotid intima-media thickness measurement.
Appendix 3. Patient medicationsMedications All Control group Exercise group P-valuespirin (%) 68 (97) 21 (95) 47 (98) 0.566
lopidogrel (%) 21 (30) 4 (18) 17 (35) 0.144
cagrelor (%) 35 (50) 14 (64) 21 (44) 0.122
nti-Coagulants (%) 2 (3) 0 (0) 2 (4) 0.331
eta-Blockers (%) 60 (86) 19 (86) 41 (85) 0.916
CE-Inhibitors (%) 42 (60) 15 (68) 27 (56) 0.344
ngiotensin Receptor Blockers (%) 6 (9) 1 (45) 5 (10) 0.415
atin (%) 67 (96) 21 (95) 46 (96) 0.942
iuretics (%) 7 (10) 3 (14) 4 (83) 0.492
alcium Channel Blockers (%) 7 (10) 2 (9) 5 (19) 0.864
itrates (%) 16 (23) 5 (23) 11 (23) 0.986NACE = angiotensin converting enzyme.
Appendix 4. Changes in Calibre 5-year all-cause mortality riskAppendix 4 – Box-and-whisker plot showing Calibre 5-year all-causemortality risk at baseline, 10week, and 12-month follow-up assessment. Lower
whisker shows minimum values, lower box line shows 25th percentile, mid-line shows median values, upper box line shows 75th percentile, and
upper whisker shows maximum values.
Appendix 5. Supplementary data
Supplementary data to this article can be found online at https://doi.org/10.1016/j.ijcard.2020.01.044.
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